AstraZeneca on Thursday said its patient-administered drug candidate with blockbuster potential has passed a registrational test in the rare autoimmune disorder myasthenia gravis.
The Phase 3 PREVAIL trial studied the drugmaker’s third-generation C5 complement inhibitor ...
↧